NXTC earnings analysis
What we found in NXTC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NextCure reported a smaller net loss of $9.8 million for Q1 2026, an improvement from $11.0 million in Q1 2025. Cash reserves decreased from $41.8 million at the end of 2025 to $29.7 million as of March 31, 2026. The company continues to focus on the development of their drug candidates, notably SIM0505, which received FDA Fast Track designation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved Net Loss
- Net loss for Q1 2026 was $9.8 million, better than $11.0 million loss in Q1 2025.
- Cash Reserves Declined
- Cash, cash equivalents, and marketable securities decreased to $29.7 million from $41.8 million at year-end 2025.
- Decreased R&D Expenses
- R&D expenses reduced to $6.8 million in Q1 2026 from $7.9 million in Q1 2025.
- Reduction in G&A Expenses
- General and administrative expenses fell to $3.3 million from $3.7 million year-over-year.
- FDA Fast Track Designation
- SIM0505 attained FDA Fast Track designation for platinum-resistant ovarian cancer.
- Operational Cash Flow Improvements
- Net cash used in operating activities reduced to $13.4 million from $13.0 million in the prior period.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Risk of Operating Losses
- The company reported net losses for Q1 2026 of $9.8 million, continuing a trend of unprofitability.
- Cash Runway Concerns
- Projected additional operating losses raise substantial doubt regarding going concern over the next year.
- Dependence on Financing
- The expectation of needing additional funding to support operations poses risk to future clinical program developments.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-4.68
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 5, 2026
- NextCure is a clinical-stage ADC-focused biopharma that acquired global (ex-China) rights to SIM0505 and is advancing two lead ADC programs (SIM0505 and LNCB74) through Phase 1. The company reported a 2025 net loss of…
- 10-Q · August 7, 2025
- NextCure reported a significantly wider operating loss and net loss in Q2 2025 as R&D spending ramped. Cash and marketable securities totaled $35.3 million as of June 30, 2025, but management disclosed "substantial…
- 10-Q · May 4, 2023
- NextCure reported a Q1 2023 net loss of $16,096 thousand (EPS -$0.58), an improvement from a net loss of $20,602 thousand (EPS -$0.74) in Q1 2022. Operating expenses declined to $17,071 thousand (driven by R&D falling…
- 10-Q · August 4, 2022
- NextCure reported Q2 2022 GAAP net loss of $17.92M (EPS -$0.65), essentially flat with Q2 2021 net loss of $17.99M (EPS -$0.65). Cash and cash equivalents rose to $28.163M at June 30, 2022 (from $12.337M at December 31,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NXTC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever